Assessement of the Knoweldge ,Attitudes,Practices of Diabetic Kidney Disease Among Diabetic Patients

April 12, 2025 updated by: Sara Abdelaziz Hassan Mahmoud, Assiut University

Assessemnt of the Knoweldge ,Attitudes and Practices of Diabetic Kidney Disease Among Diabetic Patients

This research aims to evaluate the levels of knowledge , attitudes and practices, of diabetic kidney disease among diabetic patients.

Study Overview

Status

Not yet recruiting

Detailed Description

Diabetic kidney disease is defined as patients with diabetes mellitus who have persistent proteinuria for at least three consecutive measurements per year, or a decrease in GFR (<90 ml/min/1.73m²) .Diabetic kidney disease is a severe microvascular complication frequently associated with both type 1 and type 2 diabetes mellitus, is a leading cause of renal failure. The condition can also lead to accelerated cardiovascular disease and macrovascular complications.

In Egypt, DM is a dilemma and a fast-expanding concern. According to the International Diabetes Federation (IDF), the prevalence of DM among Egyptian adults is 15.2%, which may be an underestimation.Public awareness, knowledge, and preventive practices are crucial in mitigating the onset and progression of diabetic nephropathy. Gaining insights into the general population's awareness, knowledge, attitudes, and practices (A-KAP) pertaining to this condition is crucial for the development of effective educational campaigns and preventative strategies.

Study Type

Observational

Enrollment (Estimated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sara Abdelaziz Hassan Mahmoud, Resident doctor
  • Phone Number: 01013619689
  • Email: S01013619689@gmail.com

Study Contact Backup

Study Locations

      • Assuit, Egypt
        • Assuit university
        • Contact:
      • Assuit university, Egypt
        • Assuit university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Across sectional study take anumber of diabetic patients either type 1or 2DM with age above 18yrs old to evaluate the level of knoweldge,attitudes and practices of diabetic kidney disease.

Description

Inclusion Criteria:

  • • Diabetic patients (either type 1or 2 DM ) with age above 18yrs old.

Exclusion Criteria:

  • • CKD patients due to cause other than diabetes.

    • Patients who refuse participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
evaluation of the knowledge, attitude and practice of chronic kidney disease among the diabetic patients through a questionnaire
Time Frame: Baseline

CKD screening index, which is divided into three different scales. The knowledge scale consists of 24 items regarding general knowledge of CKD, including its definition, risk factors, signs, symptoms, and complications. The attitudes scale, composed of 15 items, was used to assess the attitudes of diabetic patients toward CKD signs and symptoms and the ability to seek appropriate social and medical help related to their concerns. The practice score consists of 12 items that evaluate the health practices of each patient to prevent CKD. The validity and reliability of this screening index were examined and guaranteed and used in its arabic edition in another study .

The correct answer was given one point, zero points for an incorrect answer, a Therefore, more correct answers meant greater knowledge of DM.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Salah Abdelazeem Ahmed Seleem, Prof, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

March 28, 2025

First Submitted That Met QC Criteria

April 12, 2025

First Posted (Actual)

April 15, 2025

Study Record Updates

Last Update Posted (Actual)

April 15, 2025

Last Update Submitted That Met QC Criteria

April 12, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe